Compare Crispr Therapeutics AG (CRSP) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs LTC Properties Inc — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while LTC Properties Inc trades at $39.68 (market cap $2.05B). The key difference: Crispr Therapeutics AG is far larger — about 2.4× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.7% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | LTC | |
|---|---|---|
Market Cap | $4.97B | $2.05B |
Sector | Health | Real Estate |
52-Week High | $76.78 | $40.36 |
52-Week Low | $44.34 | $33.98 |
Enterprise Value | $3.32B | $2.90B |
Dividend Yield | — | 5.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
LTC Properties (LTC) trades at $39.67, up 2.08% today, with a bullish technical signal from moving averages and a P/E of 15.56. Revenue grew to $263M in 2025, with a net income margin of 39.09%, though recent quarters saw earnings misses. The company is expanding its SHOP portfolio, with acquisitions like the $73M purchase in July 2026, and maintains a monthly dividend of $0.19 per share.
Outlook is mixed: strong fundamentals and demographic trends support growth, but earnings volatility and high debt pose risks. Analysts are cautious, with 59% holding neutral ratings. Key catalysts include SHOP transition success, while risks involve interest rate sensitivity and execution challenges in acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
